The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations

被引:167
作者
Jones, Matthew D. [1 ]
Price, Robert [1 ]
机构
[1] Univ Bath, Pharmaceut Surface Sci Res Grp, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
关键词
dry powder inhaler; fines; fine particle excipient; ternary interactive mixtures;
D O I
10.1007/s11095-006-9012-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The inclusion of a small amount of fine particle excipient in a carrier-based dry powder inhalation system is a well researched technique to improve formulation performance and is employed in the pharmaceutical industry. The removal of intrinsic fines from a lactose carrier has been found to decrease formulation performance, whereas adding fines of many different materials into formulations increased performance. Changing the particle size of these fines, the amount added and the technique by which they were prepared also affected formulation behaviour. Despite this body of research, there is disagreement as to the mechanism by which fines improved formulation performance, with two main hypotheses presented in the literature. The first hypothesis suggested that fines prevent the drug from adhering to the strongest binding sites on the carrier, whilst the second proposed that fine particles of drug and excipient form mixed agglomerates that are more easily dispersed and deaggregated during aerosolisation. The evidence in support of each hypothesis is limited and it is clear that future research should aim to produce stronger mechanistic evidence. The investigation of interparticulate interactions using techniques such as atomic force microscopy and inverse gas chromatography may prove useful in achieving this aim.
引用
收藏
页码:1665 / 1674
页数:10
相关论文
共 59 条
[1]  
ADI H, 2005, INFLUENCE DIFFERENT
[2]  
ADI H, 2005, USE SCANNING ELECT M
[3]  
ADI H, 2004, RESP DRUG DELIVERY, V14, P553
[4]  
[Anonymous], 1992, GENERATION RESPIRABL
[5]  
ARNOLD K, 1995, Patent No. 5478578
[6]  
BOER AH, 2006, INT J PHARM, V310, P81
[7]  
Bunker Matthew, 2005, Expert Opin Drug Deliv, V2, P613, DOI 10.1517/17425247.2.4.613
[8]   Novel alternative methods for the delivery of drugs for the treatment of asthma [J].
Chan, HK ;
Chew, NYK .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (07) :793-805
[9]   Predicting the quality of powders for inhalation from surface energy and area [J].
Cline, D ;
Dalby, R .
PHARMACEUTICAL RESEARCH, 2002, 19 (09) :1274-1277
[10]   Erythritol-based dry powder of glucagon for pulmonary administration [J].
Endo, K ;
Amikawa, S ;
Matsumoto, A ;
Sahashi, N ;
Onoue, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 290 (1-2) :63-71